Cargando…

Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma

BACKGROUND: Interleukin (IL)-12 is a pro-inflammatory cytokine that mediates T-helper type 1 responses and cytotoxic T-cell activation, contributing to its utility as anti-cancer agent. Systemic administration of IL-12 often results in unacceptable toxicity; therefore, strategies to direct delivery...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paoloni, Melissa, Mazcko, Christina, Selting, Kimberly, Lana, Susan, Barber, Lisa, Phillips, Jeffrey, Skorupski, Katherine, Vail, David, Wilson, Heather, Biller, Barbara, Avery, Anne, Kiupel, Matti, LeBlanc, Amy, Bernhardt, Anna, Brunkhorst, Beatrice, Tighe, Robert, Khanna, Chand
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4474860/ https://www.ncbi.nlm.nih.gov/pubmed/26091536 http://dx.doi.org/10.1371/journal.pone.0129954

Ejemplares similares

The immunocytokine NHS-IL12 as a potential cancer therapeutic
por: Fallon, Jonathan, et al.
Publicado: (2014)

NHS-IL12, a Tumor-Targeting Immunocytokine
por: Greiner, John W, et al.
Publicado: (2021)

Rapamycin Pharmacokinetic and Pharmacodynamic Relationships in Osteosarcoma: A Comparative Oncology Study in Dogs
por: Paoloni, Melissa C., et al.
Publicado: (2010)

The Comparative Oncology Trials Consortium: Using Spontaneously Occurring Cancers in Dogs to Inform the Cancer Drug Development Pathway
por: Gordon, Ira, et al.
Publicado: (2009)

Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12
por: Morillon, Y. Maurice, et al.
Publicado: (2019)

Utilizing Immunocytokines for Cancer Therapy
por: Runbeck, Erin, et al.
Publicado: (2021)

Launching a Novel Preclinical Infrastructure: Comparative Oncology Trials Consortium Directed Therapeutic Targeting of TNFα to Cancer Vasculature
por: Paoloni, Melissa C., et al.
Publicado: (2009)

The present and future of immunocytokines for cancer treatment
por: Gout, Dennis Y., et al.
Publicado: (2022)

Current and Potential Uses of Immunocytokines as Cancer Immunotherapy
por: Sondel, Paul M., et al.
Publicado: (2012)

A Comparative Oncology Study of Iniparib Defines Its Pharmacokinetic Profile and Biological Activity in a Naturally-Occurring Canine Cancer Model
por: Saba, Corey, et al.
Publicado: (2016)

Immunocytokines: the long awaited therapeutic magic bullet in rheumatoid arthritis?
por: van de Loo, Fons A, et al.
Publicado: (2009)

Immunocytokines: a review of molecules in clinical development for cancer therapy
por: List, Thomas, et al.
Publicado: (2013)

Development of interferon γ-based immunocytokines targeting renal cancer
por: Chen, Peirong, et al.
Publicado: (2013)

Prospective Molecular Profiling of Canine Cancers Provides a Clinically Relevant Comparative Model for Evaluating Personalized Medicine (PMed) Trials
por: Paoloni, Melissa, et al.
Publicado: (2014)

Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma
por: Pedretti, M, et al.
Publicado: (2010)

Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy
por: Jung, Keunok, et al.
Publicado: (2022)

S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer
por: Klein, C
Publicado: (2014)

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
por: Klein, Christian, et al.
Publicado: (2017)

Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug—induced DNA double strand breaks from DNA double strand breaks associated with apoptosis
por: Dull, Angie B., et al.
Publicado: (2018)

Evaluation of novel immunocytokines that preferentially target high or intermediate affinity IL-2 receptors
por: Perez Horta, Zulmarie, et al.
Publicado: (2014)

Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
por: Vincent, Marie, et al.
Publicado: (2013)

Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2
por: Rekers, Nicolle H, et al.
Publicado: (2015)

Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model
por: Baniel, Claire C, et al.
Publicado: (2020)

An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2
por: Silver, Aliyah B., et al.
Publicado: (2023)

Letter to Editor
por: Khanna, Chand, et al.
Publicado: (2016)

Novel Immunocytokine IL12-SS1 (Fv) Inhibits Mesothelioma Tumor Growth in Nude Mice
por: Kim, Heungnam, et al.
Publicado: (2013)

Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation
por: Kujawski, Maciej, et al.
Publicado: (2020)

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
por: Waldhauer, Inja, et al.
Publicado: (2021)

Anti-CD70 Immunocytokines for Exploitation of Interferon-γ-Induced RIP1-Dependent Necrosis in Renal Cell Carcinoma
por: Chen, Peirong, et al.
Publicado: (2013)

The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
por: Rekers, Nicolle H., et al.
Publicado: (2018)

Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy
por: Casadesús, Ana Victoria, et al.
Publicado: (2022)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2022)

Veterinary Cooperative Oncology Group—Common Terminology Criteria for Adverse Events (VCOG‐CTCAE v2) following investigational therapy in dogs and cats
por: LeBlanc, Amy K., et al.
Publicado: (2021)

Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine
por: Cha, Seung E., et al.
Publicado: (2021)

Deep Domain Adversarial Learning for Species-Agnostic Classification of Histologic Subtypes of Osteosarcoma
por: Patkar, Sushant, et al.
Publicado: (2023)

Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression
por: Paoloni, Melissa, et al.
Publicado: (2009)

Advanced Cancer Imaging Applied in the Comparative Setting
por: Vail, David M., et al.
Publicado: (2020)

Transcriptomic profiling in canines and humans reveals cancer specific gene modules and biological mechanisms common to both species
por: Tawa, Gregory J., et al.
Publicado: (2021)

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis
por: Schwager, Kathrin, et al.
Publicado: (2009)

Immunocytokine augments local and abscopal response and animal survival when added to radiation and CTLA-4 checkpoint inhibition in a murine melanoma model
por: Morris, Zachary S, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_4vi3gm4t7qu2cv2g2pkaokvc8b